PDF file: 441-1107_details_of_the_vaccine_trials_ARR_vs._RRR.pdf
OPQ ID: 441-1107
Session: 441
Question number: Q-1107
Sessional paper: Q-1107
Title: details of the vaccine trials, ARR vs. RRR
Short description: 
Topic: vaccines
Identified concern: 
Keywords: 
Agencies: HC, PHAC, NACI
Date asked: 2022-12-12
Date tabled: 
Submitted by: Mr. Carrie (Oshawa)
Reply by: Minister of Health
Responded by: Mr. van Koeverden
Pages: 10
Status: not processed
Alert: yellow
Questions asked: 7
Questions answered: 6
Percent responded: 86%
Referenced sources: Canada.ca, World Health Organization
Referenced links: https://covid-vaccine.canada.ca/covid-19-vaccine-moderna/product-details, https://covid-vaccine.canada.ca/comirnaty/product-details
Official link: https://www.google.com/search?q=Q-1107+ourcommons.ca
PDF URL: https://ivim.ca/foi/opq/r/441-1107_details_of_the_vaccine_trials_ARR_vs._RRR.pdf
TXT URL: https://ivim.ca/foi/opq/r/441-1107.txt
Original filename: Q-1107 (Order) details of the vaccine trials, ARR vs. RRR .pdf
Local source path: C:\Users\Dmitry\Documents\CODES\OPQ-App\data-raw\OPQ\ALL OPQ TO DATE\2022\Q-1107 (Order) details of the vaccine trials, ARR vs. RRR .pdf
Machine extracted at: 2026-06-30 12:58:12

References / links:
- https://covid-vaccine.canada.ca/covid-19-vaccine-moderna/product-details
- https://covid-vaccine.canada.ca/comirnaty/product-details(c
- https://covid-vaccine.canada.ca/comirnaty/product-details(d
- Canada.ca
- World Health Organization

Machine notes:
(none)

Question text preview:
With regard to the clinical trials conducted on COVID-19 vaccine effectiveness, specifically those pertaining to the widely distributed vaccines by Pfizer/BioNTech and Moderna that Health Canada reviewed, vaccine mandates, and vaccination campaigns: (a) how many trial participants contracted COVID-19, broken down by participants in the experimental and control groups, versus the total number of participants;
(b) why was the information in (a), necessary for ascertaining the absolute risk reduction of acquiring COVID-19 following vaccination, not communicated to the general public to enable a more realistic assessment of health risks in support of informed consent;
(c) did any trial protocol deviations occur in trial participants who contracted COVID-19;
(d) was the government aware that the clinical trials did not test the ability of the vaccines to stop viral transmission before implementing the federal vaccination policy for government employees, whose stated objectives include the protection of these employees as well as their colleagues and clients from COVID-19;
(e) if the answer to (d) is affirmative, what was the justification to mandate relatively healthy government employees to get vaccinated against SARS-CoV-2;
(f) who made the decision to implement the policy in (d); and (g) how does the government justify its continued campaigns to encourage vaccination in relatively healthy Canadians, starting as young as 6 months?